Repligen (NASDAQ:RGEN) Reaches New 52-Week Low – Here’s Why

Posted by Brenda Bartman on May 13th, 2026

Repligen Corporation (NASDAQ:RGEN – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The company traded as low as $109.44 and last traded at $111.1530, with a volume of 420094 shares traded. The stock had previously closed at $113.60.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several recent research reports. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. UBS Group decreased their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $169.62.

Read Our Latest Report on Repligen

Repligen Stock Performance

The stock’s 50-day moving average is $120.17 and its 200-day moving average is $143.31. The stock has a market cap of $6.06 billion, a price-to-earnings ratio of 119.50, a P/E/G ratio of 2.23 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same quarter last year, the company earned $0.39 earnings per share. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in shares of Repligen in the first quarter worth $262,000. Jones Financial Companies Lllp increased its holdings in Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares during the last quarter. Bank of Nova Scotia increased its holdings in Repligen by 88.0% in the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after buying an additional 14,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in Repligen by 29.7% in the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after buying an additional 7,148 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

(Get Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.